Your browser doesn't support javascript.
loading
The Alzheimer's Disease Neuroimaging Initiative 3: Continued innovation for clinical trial improvement.
Weiner, Michael W; Veitch, Dallas P; Aisen, Paul S; Beckett, Laurel A; Cairns, Nigel J; Green, Robert C; Harvey, Danielle; Jack, Clifford R; Jagust, William; Morris, John C; Petersen, Ronald C; Salazar, Jennifer; Saykin, Andrew J; Shaw, Leslie M; Toga, Arthur W; Trojanowski, John Q.
Afiliação
  • Weiner MW; Department of Veterans Affairs Medical Center, Center for Imaging of Neurodegenerative Diseases, San Francisco, CA, USA; Department of Radiology, University of California, San Francisco, CA, USA; Department of Medicine, University of California, San Francisco, CA, USA; Department of Psychiatry, Univ
  • Veitch DP; Department of Veterans Affairs Medical Center, Center for Imaging of Neurodegenerative Diseases, San Francisco, CA, USA.
  • Aisen PS; Alzheimer's Therapeutic Research Institute, University of Southern California, San Diego, CA, USA.
  • Beckett LA; Division of Biostatistics, Department of Public Health Sciences, University of California, Davis, CA, USA.
  • Cairns NJ; Knight Alzheimer's Disease Research Center, Washington University School of Medicine, Saint Louis, MO, USA; Department of Neurology, Washington University School of Medicine, Saint Louis, MO, USA.
  • Green RC; Division of Genetics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.
  • Harvey D; Division of Biostatistics, Department of Public Health Sciences, University of California, Davis, CA, USA.
  • Jack CR; Department of Radiology, Mayo Clinic, Rochester, MN, USA.
  • Jagust W; Helen Wills Neuroscience Institute, University of California Berkeley, Berkeley, CA, USA.
  • Morris JC; Alzheimer's Therapeutic Research Institute, University of Southern California, San Diego, CA, USA.
  • Petersen RC; Department of Neurology, Mayo Clinic, Rochester, MN, USA.
  • Salazar J; Alzheimer's Therapeutic Research Institute, University of Southern California, San Diego, CA, USA.
  • Saykin AJ; Department of Radiology and Imaging Sciences, Indiana University School of Medicine, Indianapolis, IN, USA; Department of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, IN, USA.
  • Shaw LM; Tailored Therapeutics, Eli Lilly and Company, Indianapolis, IN, USA.
  • Toga AW; Laboratory of Neuroimaging, Institute of Neuroimaging and Informatics, Keck School of Medicine of University of Southern California, Los Angeles, CA, USA.
  • Trojanowski JQ; Institute on Aging, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA; Alzheimer's Disease Core Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA; Udall Parkinson's Research Center, Perelman School of Medicine, University of Pennsylva
Alzheimers Dement ; 13(5): 561-571, 2017 May.
Article em En | MEDLINE | ID: mdl-27931796
INTRODUCTION: The overall goal of the Alzheimer's Disease Neuroimaging Initiative (ADNI) is to validate biomarkers for Alzheimer's disease (AD) clinical trials. ADNI-3, which began on August 1, 2016, is a 5-year renewal of the current ADNI-2 study. METHODS: ADNI-3 will follow current and additional subjects with normal cognition, mild cognitive impairment, and AD using innovative technologies such as tau imaging, magnetic resonance imaging sequences for connectivity analyses, and a highly automated immunoassay platform and mass spectroscopy approach for cerebrospinal fluid biomarker analysis. A Systems Biology/pathway approach will be used to identify genetic factors for subject selection/enrichment. Amyloid positron emission tomography scanning will be standardized using the Centiloid method. The Brain Health Registry will help recruit subjects and monitor subject cognition. RESULTS: Multimodal analyses will provide insight into AD pathophysiology and disease progression. DISCUSSION: ADNI-3 will aim to inform AD treatment trials and facilitate development of AD disease-modifying treatments.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Ensaios Clínicos como Assunto / Doença de Alzheimer / Neuroimagem Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Revista: Alzheimers Dement Ano de publicação: 2017 Tipo de documento: Article País de publicação: Estados Unidos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Ensaios Clínicos como Assunto / Doença de Alzheimer / Neuroimagem Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Revista: Alzheimers Dement Ano de publicação: 2017 Tipo de documento: Article País de publicação: Estados Unidos